Adagene Inc.
ADAG- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001818838
In the last 90 days, Adagene Inc. insiders filed 4 open-market purchases and 0 sales; 35 institutions reported holding it in 13F filings for Q2 2026, worth $81.0M in total; no superinvestor holds it.
13F holders, Q4 2021
Institutional positions in Adagene Inc. as of Dec 31, 2021. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 16
- −3 vs. Q3 2021
- Shares held
- 8.37M
- −413.1K (−4.7%) vs. Q3 2021
- Total value
- $67.3M
- −$59.3M (−46.8%) vs. Q3 2021
- New holders
- 2
- 1 more added
- Sold out
- 5
- 5 more reduced
Compare with Q3 2021: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting ADAG on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 35 | $81.0M |
| Q1 2026 | 25 | $9.70M |
| Q4 2025 | 17 | $6.03M |
| Q3 2025 | 17 | $11.3M |
| Q2 2025 | 15 | $11.8M |
| Q1 2025 | 14 | $11.6M |
| Q4 2024 | 15 | $20.3M |
| Q3 2024 | 13 | $25.3M |
| Q2 2024 | 14 | $33.7M |
| Q1 2024 | 17 | $34.3M |
| Q4 2023 | 11 | $15.5M |
| Q3 2023 | 10 | $6.16M |
| Q2 2023 | 10 | $6.02M |
| Q1 2023 | 11 | $6.02M |
| Q4 2022 | 9 | $5.58M |
| Q3 2022 | 11 | $7.60M |
| Q2 2022 | 15 | $15.4M |
| Q1 2022 | 15 | $29.7M |
| Q4 2021 | 16 | $67.3M |
| Q3 2021 | 19 | $126.6M |
| Q2 2021 | 16 | $80.5M |
| Q1 2021 | 27 | $115.5M |
Institutions, Q4 2021
Shares, value and share of portfolio for each institution holding Adagene Inc.; share changes are against Q3 2021.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Morgan Stanley | 1,385,679 | $11.2M | 0.00% | +1,201+0.1% | Added |
| SC China Holding Ltd | 1,343,364 | $10.8M | 0.97% | 00.0% | Unchanged |
| FMR LLC | 1,253,065 | $10.0M | 0.00% | −1,848−0.1% | Reduced |
| Capital International Investors | 1,137,532 | $9.11M | 0.00% | 00.0% | Unchanged |
| Artal Group S.A. | 1,000,000 | $8.07M | 0.24% | 00.0% | Unchanged |
| Matthews International Capital Management LLC | 807,600 | $6.47M | 0.68% | −4,000−0.5% | Reduced |
| Hudson Bay Capital Management LP | 331,543 | $2.66M | 0.03% | 00.0% | Unchanged |
| Capital International Inc | 304,876 | $2.44M | 0.02% | 00.0% | Unchanged |
| General Atlantic LLC | 264,000 | $2.13M | 0.02% | 00.0% | Unchanged |
| OrbiMed Advisors LLC | 263,176 | $2.12M | 0.03% | −11,824−4.3% | Reduced |
| Strategic Vision Investment Ltd | 156,500 | $1.25M | 3.12% | −33,200−17.5% | Reduced |
| E Fund Management Co., Ltd. | 54,085 | $433.0K | 0.02% | −4,585−7.8% | Reduced |
| Capital International Sarl | 28,392 | $227.0K | 0.01% | 00.0% | Unchanged |
| Tudor Investment Corp Et Al | 25,976 | $210.0K | 0.00% | 00.0% | Unchanged |
| Citadel Advisors LLC | 16,753 | $134.0K | 0.00% | +16,753 | New |
| Tower Research Capital LLC (TRC) | 1,278 | $10.0K | 0.00% | +1,278 | New |
| CloudAlpha Capital Management Limited/Hong Kong | 0 | $0 | 0.00% | −300,000−100.0% | Sold out |
| Suvretta Capital Management, LLC | 0 | $0 | 0.00% | −42,722−100.0% | Sold out |
| ExodusPoint Capital Management, LP | 0 | $0 | 0.00% | −32,243−100.0% | Sold out |
| UBS Group AG | 0 | $0 | 0.00% | −1,225−100.0% | Sold out |
| Citigroup Inc | 0 | $0 | 0.00% | −654−100.0% | Sold out |